Get started
Author

Richard Nathan

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
2014 · Carlos A. DiazGranados, Andrew J. Dunning, et al. · New England Journal of Medicine · 874
PDF
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
2017 · Mark H. Wilcox, Dale N. Gerding, et al. · New England Journal of Medicine · 871
PDF
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
2017 · Richard J Vickers, Glenn S Tillotson, et al. · The Lancet Infectious Diseases · 121
PDF
Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial
2016 · Guy de Bruyn, Jamshid Saleh, et al. · Vaccine · 95
PDF
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection
2023 · Matthew D. Sims, Sahil Khanna, et al. · JAMA Network Open · 83
PDF
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization
2023 · Tracy Y. Wang, Abdus S. Wahed, et al. · Annals of Internal Medicine · 36
PDF
Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach
2023 · Matthew Greenhawt, Timothy E. Dribin, et al. · Journal of Allergy and Clinical Immunology · 24
PDF
S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial
2021 · Sahil Khanna, Colleen R. Kelly, et al. · The American Journal of Gastroenterology · 19
Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II)
2015 · Mark Wilcox, Dale Gerding, et al. · Open Forum Infectious Diseases · 19
Extremely Low Excretion of Daptomycin into Breast Milk of a Nursing Mother with Methicillin‐Resistant Staphylococcus aureus Pelvic Inflammatory Disease
2009 · Martha I. Buitrago, Jason A. Crompton, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 12
Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer
2020 · Oliver A Cornely, Kathleen M Mullane, et al. · Open Forum Infectious Diseases · 11
PDF
1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI)
2019 · Christopher Ford, Kevin Litcofsky, et al. · Open Forum Infectious Diseases · 11
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
2024 · Colleen S. Kraft, Matthew Sims, et al. · Infectious Diseases and Therapy · 9
PDF
S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection
2021 · Jessica R. Allegretti, Colleen R. Kelly, et al. · The American Journal of Gastroenterology · 5
639. Time to Recurrence of Clostridioides difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic
2021 · Thomas J Louie, Matthew Sims, et al. · Open Forum Infectious Diseases · 3
S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection
2021 · Jessica R. Allegretti, Colleen R. Kelly, et al. · The American Journal of Gastroenterology · 2
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
2024 · Colleen S. Kraft, Matthew Sims, et al. · Infectious Diseases and Therapy
PDF
Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
2023 · Matthew Sims, Charles Berenson, et al. · Antimicrobial Stewardship & Healthcare Epidemiology
PDF
US donor pushes Japan on organ transplantation
1996 · Richard Nathan · Nature Medicine
Bacterial source remains elusive
1996 · Richard Nathan · Nature Medicine
Works count: 21
Citation count: 2,316
H-index: 11
I10-index: 13
Year
Topic
Type